Δημοσιεύσεις

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 24 results:
Συντάκτης Τίτλος [ Τύπος(Desc)] Έτος
Φίλτρα: Συντάκτης is Samantas, Epaminontas  [Clear All Filters]
Journal Article
Pentheroudakis, G., Kotoula V., Koliou G-A., Karavasilis V., Samantas E., Aravantinos G., et al. (2018).  AMALTHEA: Prospective, Single-Arm Study of the Hellenic Cooperative Oncology Group (HeCOG) Evaluating Efficacy and Safety of First-Line FOLFIRI + Aflibercept for 6 Months Followed by Aflibercept Maintenance in Patients With Metastatic Colorectal Cancer.. Clin Colorectal Cancer. 17(4), e631-e637.
Pentheroudakis, G., Mavroeidis L., Papadopoulou K., Koliou G-A., Bamia C., Chatzopoulos K., et al. (2019).  Angiogenic and Antiangiogenic VEGFA Splice Variants in Colorectal Cancer: Prospective Retrospective Cohort Study in Patients Treated With Irinotecan-Based Chemotherapy and Bevacizumab.. Clin Colorectal Cancer. 18(4), e370-e384.
Rallis, G., Koletsa T., Saridaki Z., Manousou K., Koliou G-A., Kostopoulos I., et al. (2019).  Association of Notch and Hedgehog Pathway Activation With Prognosis in Early-stage Colorectal Cancer.. Anticancer Res. 39(4), 2129-2138.
Pentheroudakis, G., Kotoula V., Kouvatseas G., Charalambous E., Dionysopoulos D., Zagouri F., et al. (2014).  Association of VEGF-A splice variant mRNA expression with outcome in bevacizumab-treated patients with metastatic breast cancer.. Clin Breast Cancer. 14(5), 330-8.
Fountzilas, E., Kotoula V., Zagouri F., Giannoulatou E., Kouvatseas G., Pentheroudakis G., et al. (2016).  Disease evolution and heterogeneity in bilateral breast cancer.. Am J Cancer Res. 6(11), 2611-2630.
Briasoulis, E., Aravantinos G., Kouvatseas G., Pappas P., Biziota E., Sainis I., et al. (2013).  Dose selection trial of metronomic oral vinorelbine monotherapy in patients with metastatic cancer: a hellenic cooperative oncology group clinical translational study.. BMC Cancer. 13, 263.
Fountzilas, G., Dafni U., Papadimitriou C., Timotheadou E., Gogas H., Eleftheraki A. G., et al. (2014).  Dose-dense sequential adjuvant chemotherapy followed, as indicated, by trastuzumab for one year in patients with early breast cancer: first report at 5-year median follow-up of a Hellenic Cooperative Oncology Group randomized phase III trial.. BMC Cancer. 14, 515.
Razis, E., Pentheroudakis G., Rigakos G., Bobos M., Kouvatseas G., Tzaida O., et al. (2014).  EGFR gene gain and PTEN protein expression are favorable prognostic factors in patients with KRAS wild-type metastatic colorectal cancer treated with cetuximab.. J Cancer Res Clin Oncol. 140(5), 737-48.
Fountzilas, G., Dafni U., Bobos M., Kotoula V., Batistatou A., Xanthakis I., et al. (2013).  Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy.. BMC Cancer. 13, 163.
Korantzis, I., Kalogeras K. T., Papaxoinis G., Kotoula V., Koutras A., Soupos N., et al. (2012).  Expression of angiogenic markers in the peripheral blood of patients with advanced breast cancer treated with weekly docetaxel.. Anticancer Res. 32(10), 4569-80.
Pectasides, D., Kotoula V., Papaxoinis G., Alexopoulou Z., Dervenis C., Samantas E., et al. (2016).  Expression Patterns of Growth and Survival Genes with Prognostic Implications in Advanced Pancreatic Cancer.. Anticancer Res. 36(12), 6347-6356.
Zarkavelis, G., Kotoula V., Kolliou G-A., Papadopoulou K., Tikas I., Karavasilis V., et al. (2019).  Genetic mapping of pancreatic cancer by targeted next-generation sequencing e. ESMO Open. 4(5), e000525.
Fountzilas, G., Kotoula V., Pectasides D., Kouvatseas G., Timotheadou E., Bobos M., et al. (2013).  Ixabepilone administered weekly or every three weeks in HER2-negative metastatic breast cancer patients; a randomized non-comparative phase II trial.. PLoS One. 8(7), e69256.
Fountzilas, E., Kotoula V., Koliou G-A., Giannoulatou E., Gogas H., Papadimitriou C., et al. (2020).  Pathogenic mutations and overall survival in 3,084 patients with cancer: the Hellenic Cooperative Oncology Group Precision Medicine Initiative.. Oncotarget. 11(1), 1-14.
Papaxoinis, G., Kotoula V., Giannoulatou E., Koliou G-A., Karavasilis V., Lakis S., et al. (2018).  Phase II study of panitumumab combined with capecitabine and oxaliplatin as first-line treatment in metastatic colorectal cancer patients: clinical results including extended tumor genotyping.. Med Oncol. 35(7), 101.
Gogas, H., Dafni U., Karina M., Papadimitriou C., Batistatou A., Bobos M., et al. (2012).  Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III Trial.. Breast Cancer Res Treat. 132(2), 609-19.
Fostira, F., Tsitlaidou M., Papadimitriou C., Pertesi M., Timotheadou E., Stavropoulou A. V., et al. (2012).  Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative Oncology Group Study.. Breast Cancer Res Treat. 134(1), 353-62.
Fountzilas, E., Kotoula V., Pentheroudakis G., Manousou K., Polychronidou G., Vrettou E., et al. (2019).  Prognostic implications of mismatch repair deficiency in patients with nonmetastatic colorectal and endometrial cancer.. ESMO Open. 4(2), e000474.
Pentheroudakis, G., Kotoula V., Eleftheraki A. G., Tsolaki E., Wirtz R. M., Kalogeras K. T., et al. (2013).  Prognostic significance of ESR1 gene amplification, mRNA/protein expression and functional profiles in high-risk early breast cancer: a translational study of the Hellenic Cooperative Oncology Group (HeCOG).. PLoS One. 8(7), e70634.
Pectasides, D., Karavasilis V., Papaxoinis G., Gourgioti G., Makatsoris T., Raptou G., et al. (2015).  Randomized phase III clinical trial comparing the combination of capecitabine and oxaliplatin (CAPOX) with the combination of 5-fluorouracil, leucovorin and oxaliplatin (modified FOLFOX6) as adjuvant therapy in patients with operated high-risk stage II or. BMC Cancer. 15, 384.
Papadimitriou, C. A., Papakostas P., Karina M., Malettou L., Dimopoulos M. A., Pentheroudakis G., et al. (2011).  A randomized phase III trial of adjuvant chemotherapy with irinotecan, leucovorin and fluorouracil versus leucovorin and fluorouracil for stage II and III colon cancer: a Hellenic Cooperative Oncology Group study.. BMC Med. 9, 10.
Pentheroudakis, G., Kotoula V., Fountzilas E., Kouvatseas G., Basdanis G., Xanthakis I., et al. (2014).  A study of gene expression markers for predictive significance for bevacizumab benefit in patients with metastatic colon cancer: a translational research study of the Hellenic Cooperative Oncology Group (HeCOG).. BMC Cancer. 14, 111.
Fountzilas, G., Giannoulatou E., Alexopoulou Z., Zagouri F., Timotheadou E., Papadopoulou K., et al. (2016).  TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting.. Oncotarget. 7(22), 32731-53.
Kotoula, V., Chatzopoulos K., Lakis S., Alexopoulou Z., Timotheadou E., Zagouri F., et al. (2016).  Tumors with high-density tumor infiltrating lymphocytes constitute a favorable entity in breast cancer: a pooled analysis of four prospective adjuvant trials.. Oncotarget. 7(4), 5074-87.

Επικοινωνία

Τμήμα Ιατρικής, Πανεπιστημιούπολη ΑΠΘ, T.K. 54124, Θεσσαλονίκη
 

Συνδεθείτε

Το τμήμα Ιατρικής στα κοινωνικά δίκτυα.
Ακολουθήστε μας ή συνδεθείτε μαζί μας.

           

Σύνδεσμοι

 

Το πανεπιστήμιο

 
 

Προσωπικό & Φοιτητές